Long-term effects of chronic nicotine exposure on brain nicotinic receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 19, 2007, Pages 8155-8160

  Besson, Morgane ^a   Granon, Sylvie ^a   Mameli Engvall, Monica ^b   Cloëz Tayarani, Isabelle ^a   Maubourguet, Nicolas ^a   Cormier, Anne ^a   Cazala, Pierre ^a   David, Vincent ^a   Changeux, Jean Pierre ^a   Faure, Philippe ^a  

^a CNRS   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Exploratory behaviors; Homeostatis; Opponent process; Ventral tegmental area

Indexed keywords

ALPHA BUNGAROTOXIN I 125; EPIBATIDINE; HEMICHOLINIUM 3; METHYLLYCACONITINE; NICOTINE; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; TRITIUM; ACONITINE; ALPHA-BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR; CHRNB2 PROTEIN, MOUSE; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ADDICTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG MECHANISM; HOMEOSTASIS; LONG TERM EXPOSURE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; TOBACCO; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; ANIMAL; C57BL MOUSE; DRUG EFFECT; PHYSIOLOGY;

MUS;

ACONITINE; ANIMALS; BRAIN; MICE; MICE, INBRED C57BL; NICOTINE; RECEPTORS, NICOTINIC; VENTRAL TEGMENTAL AREA;

EID: 34249948273     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0702698104     Document Type: Article

References (41)

1. Changeux JP, Edelstein SJ (2005) Nicotinic Acetylcholine Receptors: From Molecular Biology to Cognition (Odile Jacob, New York).
2. Grenhoff J, Aston-Jones G, Svensson TH (1986) Acta Physiol Scand 128:351-358.
3. Pontieri FE, Colangelo V, La Riccia M, Pozzilli C, Passarelli F, Orzi F (1994) NeuroReport 5:2561-2564.
4. Picciotto MR (2003) Trends Pharmacol Sci 24:493-499.
5. Corrigall WA, Coen KM, Adamson KL (1994) Brain Res 653:278-284.
6. David V, Besson M, Changeux JP, Granon S, Cazala P (2006) Neuropharmacology 50:1030-1040.
7. Besson M, David V, Suarez S, Cormier A, Cazala P, Changeux JP, Granon S (2006) Psychopharmacology 187:189-199.
8. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, et al. (2005) Nature 436:103-107.
9. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Nature 391:173-177.
10. Laviolette SR, van der Kooy D (2004) Nat Rev Neurosci 5:55-65.
11. Mameli-Engvall M, Evrad A, Pons S, Maskos U, Svensson TH, Changeux JP, Faure P (2006) Neuron 50:911-921.
12. Rahman S, Zhang J, Engleman EA, Corrigall WA (2004) Neuroscience 129:415-424.
13. Dani JA, Heinemann S (1996) Neuron 16:905-908.
14. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (1997) Nature 390:401-404.
15. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, et al. (2006) J Neurosci 26:8707-8714.
16. McCallum SE, Collins AC, Paylor R, Marks MJ (2006) Psychopharmacology 184:314-327.
17. Serova L, Sabban EL (2002) J Pharmacol Exp Ther 303:896-903.
18. Granon S, Faure P, Changeux JP (2003) Proc Natl Acad Sci USA 100:9596-9601.
19. Grabus SD, Martin BR, Batman AM, Tyndale RF, Sellers E, Damaj MI (2005) Psychopharmacology 178:183-192.
20. Nomikos GG, Hildebrand BE, Panagis G, Svensson TH (1999) NeuroReport 10:697-702.
21. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, et al. (2007) Psychopharmacology 190:269-319.
22. Buisson B, Bertrand D (2002) Trends Pharmacol Sci 23:130-136.
23. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992) Mol Pharmacol 41:31-37.
24. Parker SL, Fu Y, McAllen K, Luo J, McIntosh JM, Lindstrom JM, Sharp BM (2004) Mol Pharmacol 65:611-622.
25. Mansvelder HD, Keath JR, McGehee DS (2002) Neuron 33:905-919.
26. Grace AA, Bunney BS (1983) Neuroscience 10:317-331.
27. Salas R, Pieri F, De Biasi M (2004) J Neurosci 24:10035-10039.
28. Ribeiro FM, Black SA, Prado VF, Rylett RJ, Ferguson SS, Prado MA (2006) J Neurochem 97:1-12.
29. Beeri R, Le Novere N, Mervis R, Huberman T, Grauer E, Changeux JP, Soreq H (1997) J Neurochem 69:2441-2451.
30. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA (2003) J Neurosci 23:3176-3185.
31. Giniatullin R, Nistri A, Yakel JL (2005) Trends Neurosci 28:371-378.
32. Cohen G, Roux JC, Grailhe R, Malcolm G, Changeux JP, Lagercrantz H (2005) Proc Natl Acad Sci USA 102:3817-3821.
33. Mansvelder HD, McGehee DS (2000) Neuron 27:349-357.
34. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW (1995) Science 269:1692-1696.
35. Newhouse P, Singh A, Potter A (2004) Curr Top Med Chem 4:267-282.
36. Cassels BK, Bermudez I, Dajas F, Abin-Carriquiry JA, Wonnacott S (2005) Drug Discov Today 10:1657-1665.
37. Sacco KA, Bannon KL, George TP (2004) J Psychopharmacol 18:457-474.
38. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novere N, Vincent P, Pich EM, Brulet P, Changeux JP (1995) Nature 374:65-67.
39. Faure P, Neumeister, H., Faber D, Korn H (2003) Fractals 11:233-243.
40. Grace AA, Bunney BS (1984) J Neurosci 4:2877-2890.
41. Paxinos G, Franklin KBJ (2004) The Mouse Brain in Stereotaxic Coordinates (Elsevier, San Diego).